Brokerages Set DexCom, Inc. (NASDAQ:DXCM) Target Price at $98.00

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eighteen analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $98.00.

Several research firms have recently commented on DXCM. Leerink Partners lowered their price target on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. JPMorgan Chase & Co. raised their target price on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, October 25th. Citigroup boosted their price target on shares of DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a research note on Wednesday. Oppenheimer reduced their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Finally, Stifel Nicolaus upped their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, August 23rd.

DexCom Trading Down 2.2 %

Shares of NASDAQ:DXCM traded down $1.74 during mid-day trading on Friday, reaching $77.19. 2,956,879 shares of the company were exchanged, compared to its average volume of 3,884,590. DexCom has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm's 50-day simple moving average is $73.76 and its 200 day simple moving average is $84.65. The firm has a market cap of $30.15 billion, a price-to-earnings ratio of 46.22, a P/E/G ratio of 2.46 and a beta of 1.12.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.30% of the stock is currently owned by corporate insiders.

Institutional Trading of DexCom

A number of large investors have recently bought and sold shares of DXCM. B. Riley Wealth Advisors Inc. raised its holdings in shares of DexCom by 42.3% in the third quarter. B. Riley Wealth Advisors Inc. now owns 5,590 shares of the medical device company's stock valued at $370,000 after buying an additional 1,662 shares during the last quarter. Tidal Investments LLC raised its stake in DexCom by 68.0% during the 3rd quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company's stock valued at $2,463,000 after acquiring an additional 14,872 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in DexCom during the 3rd quarter valued at approximately $381,000. World Investment Advisors LLC acquired a new stake in DexCom during the 3rd quarter worth approximately $2,351,000. Finally, Sanctuary Advisors LLC grew its stake in shares of DexCom by 32.2% in the 3rd quarter. Sanctuary Advisors LLC now owns 14,835 shares of the medical device company's stock valued at $1,080,000 after purchasing an additional 3,615 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.